Ken Griffin Iveric Bio, Inc. Call Options Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	BUY	$26.24 - $39.63 $2.34 Million - $3.53 Million	89,000 Added 38.33%	321,200 $12.6 Million
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $2.13 Million - $2.8 Million	-113,900 Reduced 32.91%	232,200 $5.65 Million
Q4 2022 Feb 14, 2023	SELL	$17.24 - $23.95 $2.42 Million - $3.36 Million	-140,400 Reduced 28.86%	346,100 $7.41 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $2.09 Million - $4.13 Million	221,900 Added 83.86%	486,500 $8.73 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.